Valuation dashboard for TG Therapeutics, Inc. (TGTX) with P/E 18.34, P/B 13.11, EV/EBITDA N/A and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders.
Analysis Summary
TG Therapeutics, Inc. reported revenue of $616.3M in the most recent fiscal year, growing at a 5-year CAGR of 426.7%.
Trailing-twelve-month margins: gross margin 82.4%, operating margin 17.1%, net margin 55.2%.
Balance sheet quality for TGTX: current ratio of 4.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 18.34 |
| Price / Book | 13.11 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-59.48 |
| vs Current Price | -206.5% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| TGTX | TG Therapeutics, Inc. | $8.5B | 18.34 | 13.11 | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $9.3B | 19.78 | -0.3% | |
| PCVX | Vaxcyte, Inc. | $8.5B | 3.10 | -37.6% | |
| KRYS | Krystal Biotech, Inc. | $9.9B | 39.88 | 7.17 | |
| KYMR | Kymera Therapeutics, Inc. | $9.6B | 7.56 | ||
| ACLX | Arcellx, Inc. | $6.7B | 16.10 | ||
| ALKS | Alkermes plc | $7.7B | 112.07 | 4.16 | |
| IMVT | Immunovant, Inc. | $7.5B | 9.99 |
Price
| Price | $55.85 |
| Market Cap | $8.5B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Gross Margin | 82.36% |
| Operating Margin | 17.05% |
| Net Margin | 55.22% |
Related companies: ACLX · ALKS · ARWR · CRSP · IMVT · KRYS · KYMR
Explore sector: Healthcare · Biotechnology
More sections of TGTX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks